Publications

• Tu MM, Lee FYF, Jones RT, Kimball AK, Saravia E, Graziano RF, Coleman B, Menard K, Yan J, Michaud E, Chang H, Abdel-Hafiz HA, Rozhok AI, Duex JE, Agarwal N, Chauca-Diaz A, Johnson LK, Ng TL, Cambier JC, Clambey ET, Costello JC, Korman AJ, Theodorescu D. Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy. Sci Adv. 2019 Feb 20;5(2):eaav2437. https://advances.sciencemag.org/content/5/2/eaav2437.
• Morgan MJ*, Fitzwalter BE, Owens CR, Powers RK, Sottnik JL, Gamez G, Costello JC, Theodorescu D,* Thorburn A. Metastatic cells are preferentially vulnerable to lysosomal inhibition. Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):E8479-E8488. https://www.pnas.org/content/115/36/E8479.
• Ahmed M, Sottnik JL, Dancik GM, Sahu D, Hansel DE, Theodorescu D*, Schwartz MA*. An osteopontin/CD44 axis in RhoGDI2-mediated metastasis suppression. Cancer Cell. 2016 Sep 12;30(3):432-443. https://www.cell.com/cancer-cell/fulltext/S1535-6108(16)30385-3.
• Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen SB, Costello JC, Theodorescu D, Cech TR. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science. 2015 Feb 27;347(6225):1006-1010. http://science.sciencemag.org/content/347/6225/1006.
• Yan C, Liu D, Li L, Wempe MF, Guin S, Khanna M, Meier J, Hoffman B, Owens C, Wysoczynski CL, Nitz MD, Knabe WE, Ahmed M, Brautigan DL, Paschal BM, Schwartz MA, Jones DN, Ross D, Meroueh SO, Theodorescu D. Discovery and characterization of small molecules that target the GTPase Ral. Nature. 2014 Nov 20;515(7527):443-447. https://www.nature.com/articles/nature13713.
• Guin S, Pollard C, Ru Y, Ritterson Lew C, Duex JE, Dancik G, Owens C, Spencer A, Knight S, Holemon H, Gupta S, Hansel D, Hellerstein M, Lorkiewicz P, Lane AN, Fan TW, Theodorescu D. Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage disease. J Natl Cancer Inst. 2014 Apr 3;106(5). pii: dju062. https://academic.oup.com/jnci/article/106/5/dju062/2607084
• Said N, Frierson HF, Sanchez-Carbayo M, Brekken RA, Theodorescu D. Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J Clin Invest. 2013 Feb;123(2):751-766. https://www.jci.org/articles/view/64782.
• Overdevest JB, Knubel KH, Duex JE, Thomas S, Nitz MD, Harding MA, Smith SC, Frierson HF, Conaway M, Theodorescu D. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):E3588-3596. https://www.pnas.org/content/109/51/E3588.
• Said N, Sanchez-Carbayo M, Smith SC, Theodorescu D. RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J Clin Invest. 2012 Apr;122(4):1503-1518. https://www.jci.org/articles/view/61392.
• Smith SC, Baras AS, Dancik G, Ru Y, Ding KF, Moskaluk CA, Fradet Y, Lehmann J, Stöckle M, Hartmann A, Lee JK, Theodorescu D. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol. 2011 Feb;12(2):137-143. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70296-5/fulltext.
• Said N, Smith S, Sanchez-Carbayo M, Theodorescu D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest. 2011 Jan;121(1):132-147. https://www.jci.org/articles/view/42912.
• Wu Y, Moissoglu K, Wang H, Wang X, Frierson HF, Schwartz MA, Theodorescu D. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5807-5812. https://www.pnas.org/content/106/14/5807.
• Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, Grimshaw A, Theodorescu D. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13086-13091. https://www.pnas.org/content/104/32/13086.
• Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006 Mar;7(3):230-240. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(06)70584-8/fulltext.

(*corresponding author)